Clinical Trial

A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 25, 2025 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This trial is a multicenter, open, single arm, dose increasing and extended clinical trial. The dose was increased according to the "3 + 3" rule. Patients with recurrent or refractory CD20 positive B-cell non-Hodgkin's lymphoma were selected to evaluate the safety, tolerance (DLT, MTD) and pharmacokinetic (PK) characteristics of TRS005 by intravenous drip.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-05-24; most recent amendment 2025-06-18.
Status change: Recruiting → Active, Not Recruiting 2025-06-18
Trial Details
NCT Number NCT05395533
Lead Sponsor Zhejiang Teruisi Pharmaceutical Inc.
Conditions CD20-positive B-cell Non-Hodgkin Lymphoma
Enrollment 147 participants
Start Date 2020-09-08
Primary Completion 2025-07-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-25